# Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

> **NCT00368329** · PHASE1 · TERMINATED · sponsor: **Stanford University** · enrollment: 4 (actual)

## Conditions studied

- Esophageal Neoplasms
- Carcinoma, Squamous Cell
- Adenocarcinoma
- Esophageal Cancer

## Interventions

- **DRUG:** Capecitabine (Xeloda)
- **DRUG:** [18-F] Fluorodeoxyglucose (FDG)
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00368329
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368329, "Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00368329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*